NCT04988152View on ClinicalTrials.gov

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

September 2, 2021

Study Completion Date

December 7, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

sotrovimab

sotrovimab IV infusion, single dose

OTHER

Placebo to Biologic

Sterile 0.9% (w/v) sodium chloride solution

BIOLOGICAL

sotrovimab

Sotrovimab IM injection, single dose

OTHER

Placebo to Biologic

Sterile 0.9% (w/v) sodium chloride solution

Trial Locations (2)

91206

Investigative Site, Glendale

92801

Investigative Site, Anaheim

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Vir Biotechnology, Inc.

INDUSTRY